glp1-ozempic
Compounded Semaglutide: What It Is and the Risks to Know
Last reviewed: May 2026 · Haute MD Editorial Team
Compounded semaglutide — semaglutide produced by compounding pharmacies rather than Novo Nordisk — emerged as a dramatically lower-cost alternative to branded Ozempic and Wegovy during the FDA drug shortage period (2022-2024). At $150-$400/month versus $900-$1,350/month for branded products, compounded versions made GLP-1 therapy accessible to patients who could not afford or access branded medications. However, the FDA designated the semaglutide shortage as resolved in early 2025, changing the legal status of compounded semaglutide and raising important questions about quality, purity, and regulatory oversight.
What compounded semaglutide is and how it differs from branded
Pharmaceutical compounding is the practice of preparing customized medications for specific patients — traditionally used when commercially available medications are unavailable, when a patient needs a different dose, or when they have allergies to excipients in the commercial product. During the FDA shortage, compounding pharmacies produced semaglutide in vials for injection, offering significant cost reduction. The active molecule — semaglutide — is the same. However, branded Ozempic and Wegovy use proprietary formulations including stabilizers and delivery systems optimized for absorption and tolerability. Compounded versions may use different salts of semaglutide (semaglutide acetate rather than semaglutide sodium) or different concentrations, and lack the standardized manufacturing controls of FDA-approved products.
Current regulatory status — what changed in 2025
In early 2025, the FDA determined that the shortage of semaglutide injection products had been resolved — removing the shortage designation that had allowed compounding pharmacies to legally produce semaglutide at scale under 503B outsourcing facility status. With the shortage designation removed, producing compounded semaglutide for general dispensing (as opposed to patient-specific compounding with a valid prescription documenting a specific patient need beyond what commercial products can meet) is no longer consistent with FDA regulations. Many compounding pharmacies have begun winding down semaglutide production; others continue operating in legally ambiguous territory. The landscape is evolving — verify current status with your prescribing physician.
Risk considerations for patients who used or are considering compounded semaglutide
Quality variability — compounding pharmacies are regulated by state pharmacy boards rather than FDA, with significant variation in standards. Some 503B outsourcing facilities maintain high standards; some smaller compounders do not. FDA inspections have found compounded semaglutide products with incorrect concentrations, sterility concerns, and impurities. Semaglutide acetate vs. sodium — some compounded products use semaglutide acetate rather than the semaglutide sodium in branded products; the clinical equivalence of these salts has not been established in published trials. Patient risk — injection of non-sterile or incorrectly concentrated product carries real clinical risk, including infection and dosing errors.
Frequently Asked Questions
Is compounded semaglutide safe?
The safety of compounded semaglutide depends entirely on the quality of the specific compounding facility producing it. High-quality 503B outsourcing facilities with rigorous quality control may produce product comparable in safety to branded medications. Lower-quality compounders present real risks of contamination, incorrect concentration, and impurities. Without FDA oversight of the specific product, patients cannot verify quality independently. The FDA has issued multiple alerts about compounded semaglutide quality concerns.
Is compounded semaglutide still legal?
As of early 2025, the FDA removed the shortage designation for semaglutide, making large-scale compounding for general dispensing legally questionable under federal law. Patient-specific compounding with a valid documented medical reason may still be legal in some circumstances. The regulatory situation is evolving and varies by state. Discuss current status with your prescribing physician — they are responsible for understanding the legal framework for medications they prescribe.
What should I do if I was taking compounded semaglutide?
Discuss with your prescribing physician. Options include — transitioning to branded Ozempic or Wegovy (with insurance prior authorization if applicable, or at out-of-pocket cost), applying for manufacturer patient assistance programs (Novo Nordisk offers assistance for eligible patients), using telehealth platforms that have access to branded products at negotiated rates, or pausing treatment with expectation management about weight regain.
How does compounded semaglutide compare in effectiveness?
No head-to-head clinical trials compare compounded and branded semaglutide directly. In theory, if the active molecule is equivalent and bioavailability is similar, effectiveness should be comparable. Patient-reported outcomes from the compounded shortage period are generally consistent with branded product data — suggesting clinical similarity in many cases. The concern is not primarily efficacy but quality consistency and regulatory oversight.
Get Help Now
Speak with a Haute MD Internal Medicine physician
Dr. Alexander Golberg
Internal Medicine · New York, NY
View Profile
Dr. Kern Brar
MD
Internal Medicine · Oceanside, CA
View Profile
Dr. Patrick Nolan
Chief Medical Officer, D.O.
Internal Medicine · Palm Beach, FL
View ProfileAre you a Internal Medicine physician?
Join Haute MD Network and have your profile featured alongside these answers.
Apply for the NetworkRelated Guides
Guide · GLP1-OZEMPIC
Ozempic vs. Wegovy: Same Drug, Different Uses
Ozempic and Wegovy both contain semaglutide but at different doses for different indications. Learn the differences, which is right for you, and how insurance affects access.
Read GuideGuide · GLP1-OZEMPIC
What Happens When You Stop GLP-1 Medications?
Most patients regain 50-70% of lost weight within a year of stopping GLP-1 medications. Learn why this happens and what strategies reduce regain.
Read Guide